Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor ; day:18 ; month:4 ; year:2020 ; pages:1-18
Clinical pharmacokinetics ; (18.4.2020), 1-18
- Urheber
-
James, Angela Joubert
Smith, Catherine C.
Litzow, Mark
Perl, Alexander E.
Altman, Jessica K.
Shepard, Dale
Kadokura, Takeshi
Souda, Kinya
Patton, Melanie
Lu, Zheng
Liu, Chaofeng
Moy, Selina
Levis, Mark J.
Bahceci, Erkut
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-020-00888-w
- URN
-
urn:nbn:de:101:1-2020062923565702717642
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- James, Angela Joubert
- Smith, Catherine C.
- Litzow, Mark
- Perl, Alexander E.
- Altman, Jessica K.
- Shepard, Dale
- Kadokura, Takeshi
- Souda, Kinya
- Patton, Melanie
- Lu, Zheng
- Liu, Chaofeng
- Moy, Selina
- Levis, Mark J.
- Bahceci, Erkut
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Newer Tyrosine Kinase Inhibitors for CML
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
Second-generation inhibitors of Bruton tyrosine kinase
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
The effects of tyrosine kinase inhibitors in pancreatic cancer
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Newer Tyrosine Kinase Inhibitors for CML
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
Second-generation inhibitors of Bruton tyrosine kinase
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
The effects of tyrosine kinase inhibitors in pancreatic cancer
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
Newer Tyrosine Kinase Inhibitors for CML
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
Second-generation inhibitors of Bruton tyrosine kinase
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
The effects of tyrosine kinase inhibitors in pancreatic cancer
Synthesis of a Bruton’s Tyrosine Kinase Inhibitor
Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia